Is HYPD or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% Phio Pharmaceuticals N/A -77.34% -70.87%

Is PHIO or IXHL more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% Incannex Healthcare N/A -81.01% -76.11%

Do analysts prefer APLM or PHIO?

Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,300.00%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, APLM or PHIO?

Phio Pharmaceuticals has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.06 -$10.94M N/A N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A

Is APLM or PHIO more profitable?

Apollomics' return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Phio Pharmaceuticals N/A -77.34% -70.87%

Do analysts recommend INMB or PHIO?

Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,300.00%. Given Phio Pharmaceuticals' higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INMB or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Phio Pharmaceuticals N/A -77.34% -70.87%

Phio Pharmaceuticals (PHIO) Competitors

$1.00 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.01 +0.01 (+0.90%)

As of 07/2/2026 07:21 PM Eastern

Compare

PHIO vs. HYPD, IXHL, MGX, APLM, and INMB

Should you buy Phio Pharmaceuticals stock or one of its competitors? MarketBeat compares Phio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phio Pharmaceuticals include Hyperion DeFi (HYPD), Incannex Healthcare (IXHL), Metagenomi (MGX), Apollomics (APLM), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry.

How does Phio Pharmaceuticals compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Hyperion DeFi had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 2 mentions for Hyperion DeFi and 1 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 1.00 beat Hyperion DeFi's score of 0.88 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperion DeFi	Positive
Phio Pharmaceuticals	Positive

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Hyperion DeFi presently has a consensus target price of $6.95, suggesting a potential upside of 123.47%. Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,300.00%. Given Phio Pharmaceuticals' higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals' return on equity of -77.34% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Hyperion DeFi has a beta of 2.49, suggesting that its share price is 149% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Phio Pharmaceuticals has lower revenue, but higher earnings than Hyperion DeFi. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	58.21	-$45.31M	-$9.95	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

Summary

Phio Pharmaceuticals beats Hyperion DeFi on 7 of the 13 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Incannex Healthcare?

Phio Pharmaceuticals (NASDAQ:PHIO) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Incannex Healthcare. MarketBeat recorded 1 mentions for Phio Pharmaceuticals and 0 mentions for Incannex Healthcare. Phio Pharmaceuticals' average media sentiment score of 1.00 beat Incannex Healthcare's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phio Pharmaceuticals	Positive
Incannex Healthcare	Neutral

Phio Pharmaceuticals has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Incannex Healthcare	$90K	528.01	-$46.88M	-$1.55	N/A

Phio Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.95, suggesting that its stock price is 595% more volatile than the broader market.

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals' return on equity of -77.34% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Incannex Healthcare	N/A	-81.01%	-76.11%

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,300.00%. Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 353.40%. Given Phio Pharmaceuticals' higher probable upside, research analysts plainly believe Phio Pharmaceuticals is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Phio Pharmaceuticals beats Incannex Healthcare on 9 of the 12 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Metagenomi?

Phio Pharmaceuticals (NASDAQ:PHIO) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 1,300.00%. Metagenomi has a consensus price target of $9.00, suggesting a potential upside of 614.29%. Given Phio Pharmaceuticals' higher probable upside, research analysts plainly believe Phio Pharmaceuticals is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Phio Pharmaceuticals has higher earnings, but lower revenue than Metagenomi. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Metagenomi	$25.21M	1.88	-$87.87M	-$2.30	N/A

Phio Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Phio Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Metagenomi	-384.61%	-51.23%	-36.62%

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Metagenomi. MarketBeat recorded 1 mentions for Phio Pharmaceuticals and 0 mentions for Metagenomi. Phio Pharmaceuticals' average media sentiment score of 1.00 beat Metagenomi's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phio Pharmaceuticals	Positive
Metagenomi	Neutral

Summary

Phio Pharmaceuticals and Metagenomi tied by winning 8 of the 16 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Apollomics?

Apollomics (NASDAQ:APLM) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Apollomics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Phio Pharmaceuticals' average media sentiment score of 1.00 beat Apollomics' score of 0.59 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Positive
Phio Pharmaceuticals	Positive

Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,300.00%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.06	-$10.94M	N/A	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Summary

Phio Pharmaceuticals beats Apollomics on 7 of the 11 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,300.00%. Given Phio Pharmaceuticals' higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals' return on equity of -77.34% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Phio Pharmaceuticals has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	903.72	-$45.93M	-$1.67	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

In the previous week, INmune Bio had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 2 mentions for INmune Bio and 1 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 1.00 beat INmune Bio's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Neutral
Phio Pharmaceuticals	Positive

INmune Bio has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Summary

Phio Pharmaceuticals beats INmune Bio on 9 of the 15 factors compared between the two stocks.

Get Phio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHIO vs. The Competition

Export

Metric	Phio Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.62M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.72	20.06	28.02	24.70
Price / Sales	N/A	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.53	4.32	10.96	6.46
Net Income	-$8.70M	$64.45M	$3.57B	$337.01M
7 Day Performance	3.09%	2.97%	2.12%	1.69%
1 Month Performance	-5.66%	6.83%	5.25%	3.81%
1 Year Performance	-58.92%	29.07%	33.29%	23.90%

Phio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHIO Phio Pharmaceuticals	4.1636 of 5 stars	$1.00 flat	$14.00 +1,300.0%	-58.9%	$11.62M	N/A	N/A	10	Positive News
HYPD Hyperion DeFi	3.4216 of 5 stars	$3.10 -2.5%	$5.65 +82.3%	-80.5%	$46.99M	$1.04M	N/A	40	Positive News Analyst Forecast
IXHL Incannex Healthcare	2.1917 of 5 stars	$3.75 +3.6%	$18.00 +380.0%	-36.7%	$45.01M	$90K	N/A	3	Gap Down
MGX Metagenomi	2.3722 of 5 stars	$1.18 -2.1%	$9.00 +666.0%	-23.8%	$44.24M	$22.33M	N/A	236
APLM Apollomics	0.7489 of 5 stars	$19.95 -6.1%	N/A	+200.7%	$43.80M	$8.50M	N/A	45

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHIO) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. HYPD, IXHL, MGX, APLM, and INMB

How does Phio Pharmaceuticals compare to Hyperion DeFi?

Summary

How does Phio Pharmaceuticals compare to Incannex Healthcare?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Summary

How does Phio Pharmaceuticals compare to Apollomics?

Summary

How does Phio Pharmaceuticals compare to INmune Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. HYPD, IXHL, MGX, APLM, and INMB

How does Phio Pharmaceuticals compare to Hyperion DeFi?

Does the media prefer HYPD or PHIO?

Do institutionals and insiders hold more shares of HYPD or PHIO?

Do analysts rate HYPD or PHIO?

Is HYPD or PHIO more profitable?

Which has more risk and volatility, HYPD or PHIO?

Which has higher valuation & earnings, HYPD or PHIO?

Summary

How does Phio Pharmaceuticals compare to Incannex Healthcare?

Does the media favor PHIO or IXHL?

Which has higher earnings and valuation, PHIO or IXHL?

Which has more volatility and risk, PHIO or IXHL?

Do insiders & institutionals have more ownership in PHIO or IXHL?

Is PHIO or IXHL more profitable?

Do analysts prefer PHIO or IXHL?

Summary

How does Phio Pharmaceuticals compare to Metagenomi?

Do institutionals & insiders have more ownership in PHIO or MGX?

Do analysts prefer PHIO or MGX?

Which has better earnings and valuation, PHIO or MGX?

Which has more risk and volatility, PHIO or MGX?

Is PHIO or MGX more profitable?

Does the media favor PHIO or MGX?

Summary

How does Phio Pharmaceuticals compare to Apollomics?

Which has more risk and volatility, APLM or PHIO?

Does the media favor APLM or PHIO?

Do analysts prefer APLM or PHIO?

Which has preferable earnings and valuation, APLM or PHIO?

Do insiders and institutionals hold more shares of APLM or PHIO?

Is APLM or PHIO more profitable?

Summary

How does Phio Pharmaceuticals compare to INmune Bio?

Do analysts recommend INMB or PHIO?

Is INMB or PHIO more profitable?

Do insiders & institutionals have more ownership in INMB or PHIO?

Which has preferable valuation & earnings, INMB or PHIO?

Does the media favor INMB or PHIO?

Which has more volatility & risk, INMB or PHIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools